Renata (DHA:RENATA) Other Financing: BDT3,234 Mil (TTM As of Mar. 2026)


DHA:RENATA Renata PLC DHA:RENATA
85 GF Score
Price BDT460.50
GF Value BDT812.71
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Renata Other Financing?

Renata DHA:RENATA +0.20% 85 Other Financing is BDT3,234 Mil as of Mar. 2026. GuruFocus rates DHA:RENATA with a GF Score™ of 85/100 and a GF Value™ of BDT812.71 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Renata's Other Financing for the three months ended in Mar. 2026 was BDT-0 Mil.

Renata's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was BDT3,234 Mil.

Renata Other Financing Historical Data

* Premium members only.

The historical data trend for Renata's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renata Other Financing Chart

Renata Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00

Renata Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.01 0.00 3,235.25 -0.10
DHA:RENATA
85GF Score
Renata PLC DHA:RENATA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renata Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT3,234 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of BDT3,234 Mil mean?
Renata (DHA:RENATA) has a Other Financing of BDT3,234 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Renata and its competitors.
Is Renata's Other Financing too high?
Renata's current Other Financing is BDT3,234 Mil. Overall, Renata has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's Other Financing compare to ZTS and UTHR?
Renata's Other Financing of BDT3,234 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Renata and its competitors. Renata's current Other Financing is BDT3,234 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT812.71, compared to a current price of BDT460.50 — trading 43.3% below its estimated fair value. The current Other Financing is BDT3,234 Mil. Renata's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Renata (DHA:RENATA), the current Other Financing is BDT3,234 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renata (DHA:RENATA) Overvalued in 2026?

Based on GuruFocus' analysis, Renata stock appears to be undervalued. The current stock price of BDT460.50 is trading 43.3% below its estimated GF Value™ of BDT812.71. GuruFocus considers Renata to be Significantly Undervalued.

Key valuation signals for DHA:RENATA:

  • Other Financing: BDT3,234 Mil
  • GF Value™: BDT812.71 vs. price of BDT460.50 (43.3% below fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renata Business Description

Address Plot Number 1, Milk Vita Road, Section-7, GPO Box No. 303, Mirpur, Dhaka, BGD, 1216
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
85GF Score

Get the complete analysis for DHA:RENATA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT460.50
Price
BDT812.71
GF Value